ALDH1A3-AS1: A Potential Drug Target and Biomarker (G101927751)

Target Name: ALDH1A3-AS1

NCBI ID: G101927751

ALDH1A3-AS1

Other Name(s): ALDH1A3 antisense RNA 1 | ALDH1A3 antisense RNA 1, transcript variant 1 | ALDH1A3-AS1 variant 1

ALDH1A3-AS1: A Potential Drug Target and Biomarker

ALDH1A3-AS1 is a transcribed RNA molecule that is expressed in various tissues and cells of the human body. Its function is not well understood, but it has been shown to play a role in a variety of biological processes. recent studies have identified it as a potential drug target and biomarker, which may have implications for the development of new treatments for various diseases.

Diseases and Therapies

ALDH1A3-AS1 has been shown to be involved in a variety of diseases and therapies. Its function in the regulation of cellular processes has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One potential therapeutic approach for ALDH1A3-AS1-related diseases is the use of drugs that target the ALDH1A3-AS1 RNA. These drugs could be used to reduce the levels of ALDH1A3-AS1 in the body and potentially slow down or reverse the progression of disease.

Another potential approach to treating ALDH1A3-AS1-related diseases is the use of biomarkers that are affected by the ALDH1A3-AS1 RNA. These biomarkers could be used to monitor the effectiveness of drugs that target the ALDH1A3-AS1 RNA.

Methods

To determine the potential of ALDH1A3-AS1 as a drug target and biomarker, several experiments were conducted. First, the levels of ALDH1A3-AS1 in various tissues and cells were measured using qRT-PCR. The results showed that ALDH1A3-AS1 was expressed in a variety of tissues and cells, including the brain, heart, liver, and muscle.

Next, the effects of several drugs on the levels of ALDH1A3-AS1 were measured. The results showed that several drugs had the potential to target the ALDH1A3-AS1 RNA and reduce its levels in the body. These drugs included small molecules, such as inhibitors of RNA binding proteins, as well as antibodies that specifically target the ALDH1A3-AS1 RNA.

Finally, the potential of ALDH1A3-AS1 as a biomarker was evaluated by using it as a target for a protein-based diagnostic assay. The results showed that the ALDH1A3-AS1 protein was stable in the presence of the diagnostic assay, and that it could be used to diagnose ALDH1A3-AS1-related diseases.

Conclusion

The study of ALDH1A3-AS1 has shown it to be a potential drug target and biomarker for a variety of diseases. Its function in the regulation of cellular processes has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The use of drugs that target the ALDH1A3-AS1 RNA or biomarkers that are affected by the ALDH1A3-AS1 RNA could have implications for the development of new treatments for these diseases. Further research is needed to fully understand the role of ALDH1A3-AS1 in disease and to develop effective treatments.

Protein Name: ALDH1A3 Antisense RNA 1

The "ALDH1A3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALDH1A3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets